Clinical Trial

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 19, 2024 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a randomised, open-label, multicenter, active-controlled, parallel-design, phase III clinical trial. The purpose of this study to compare the efficacy and safety of Insulin Degludec/Liraglutide Injection with XULTOPHY® once daily via subcutaneous injection in Chinese Subjects with Type 2 Diabetes.
Trial Details
NCT Number NCT06559722
Lead Sponsor Tonghua Dongbao Pharmaceutical Co.,Ltd
Conditions Type 2 Diabetes
Enrollment 510 participants
Start Date 2024-08
Primary Completion 2025-10 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2024-08-19